This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
AstraZeneca (AZN) - The pharma giant and its partner MedImmune say results for Phase III MYSTIC trial of Imfinzi, its non-small cell lung cancer (NSCLC) treatment, are now not expected until the second half of this year having guided towards H1 previously. AZN shells fell 16% in July after the trial failed in phase II.
Capita (CPI) - The Sunday Times reports the outsourcer is planning to sell £700m worth of assets as part of the company's transformation programme, although the firm has hit out at suggestions of a 'fire sale'.
Hikma Pharmaceuticals (HIK) - The drugmaker and its partner Vectura announce the US FDA have upheld a previous decision on their generic version of GSK’s Advair Diskus, requesting an additional clinical endpoint study, with the results not expected until 2019.
GKN (GKN) - Melrose Industries makes final 467p offer for GKN (43% premium to 5 January closing price, the week before the first bid); GKN shareholders to own 60% of new combined group with 1.69 shares (up from 1.49) and unchanged 81p cash (17.3%). GKN publishes their 2nd response circular, rejecting Melrose’s prior offer.
(Sources: Company newswires, Bloomberg, CNBC, FT, Reuters, Wall Street Journal)
For more information on any of these individual news items, call into the trading floor
| Stock | Code | Close | High | Low |
| BARCLAYS | BARC | -0.7% | 0.4% | -1.1% |
| HSBC HOLDINGS | HSBA | 0.4% | 0.5% | -0.2% |
| INMARSAT | ISAT | -6.7% | -0.1% | -9.2% |
| INTERSERVE | IRV | -6.4% | 2.1% | -12.9% |
| LLOYDS BANKING GROUP | LLOY | -0.3% | 0.4% | -0.6% |
| ROYAL BANK OF SCOTLAND | RBS | -0.5% | 0.3% | -1.5% |
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research